https://webdev.viracor-eurofins.com/images/Viracor_Eurofins_PDFlogo.jpg 1001 NW Technology Drive, Lee's Summit, MO 64086 // (800) 305-5198 // (816) 347-0143 Fax // info@viracor-eurofins.com

Pneumococcal Avidity Panel (12 Serotype)

Test Code: 401734P

Tests in this Panel

Pneumo Ab Type 1 Avidity
Pneumo Ab Type 3 Avidity
Pneumo Ab Type 4 Avidity
Pneumo Ab Type 8 Avidity
Pneumo Ab Type 9 (9N) Avidity
Pneumo Ab Type 12 (12F) Avidity
Pneumo Ab Type 14 Avidity
Pneumo Ab Type 19 (19F) Avidity
Pneumo Ab Type 26 (6B) Avidity
Pneumo Ab Type 51 (7F) Avidity
Pneumo Ab Type 56 (18C) Avidity
Pneumo Ab Type 23 (23F) Avidity

Clinical and Procedure

Clinical Utility

The avidity of antibody induced by a vaccine is an independent correlate of protection and this information is an important supplement to the measurement of antibody titer. The ability to generate higher avidity antibodies is a key aspect of a fully functional immune response. Avidity functions is an important determinant of protective efficacy against pneumococci. There is a strong correlation between avidity and opsonophagocytic activity.

Procedure

Multiplexed microsphere preparations, each coated with one Pne-PS serotype, are incubated with patient serum that has been preadsorbed with cell wall polysaccharide. After washing, varying concentrations of ammonium thiocyanate or PBS are added. Bound antibodies are detected with an antibody that recognizes human IgG. The IgG antibody concentration is calculated in samples from a standard curve referenced to WHO standard serum 89SF. The avidity is calculated based on binding with various concentrations of thiocyanate. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.

Turnaround Time

5-7 business days from receipt of specimen

Specimen Information

Specimen Type	Order Code	CPT Code	NY Approved	Volume	Assay Range
serum	401734P	86317	Yes	1 mL (min. 100 uL)	NA

Special Instructions
- Collect 1 mL, ambient, frozen, or refrigerated, so speical shipping requirements.

Disclaimer

Specimens are approved for testing in New York only when indicated in the Specimen Information field above.

https://webdev.viracor-eurofins.com/images/Viracor_Eurofins_PDFlogo.jpg 1001 NW Technology Drive, Lee's Summit, MO 64086 // (800) 305-5198 // (816) 347-0143 Fax // info@viracor-eurofins.com

The CPT codes provided are based on Viracor Eurofins' interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor Eurofins assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.

References

Usinger WR, Lucas AH. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. *Infect Immun.* 1999 May;67(5):2366-70.

Ekstrom N, Ahman H, Verho J, et al. Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. *Infect Immun* . 2005 Jan;73(1):369-77.

Musher DM, Phan H M, Watson D A, Baughn R E. Antibody to capsular polysaccharide of Streptococcus pneumoniae at the time of hospital admission for Pneumococcal pneumonia. *J Infect Dis* . 2000;182(1):158-67.

Sun Y, Young-IL H, Moon NH. Avidity, Potency, and Cross-Reactivity of Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide Serotype 6B. *Infect Immun* . 2001 Jan;69(1):336-44.

Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. *Clin Infect Dis* . 1999 Aug;29(2):281-8.

Vermont CL, van Dijken HH, van Limpt CJP, de Groot R, Van Alphen L, van den Dobbelsteen GPJM. Antibody Avidity and Immunoglobulin G Isotype Distribution following Immunization with a Monovalent Meningococcal B Outer Membrane Vesicle Vaccine. *Infect Immun* . 2002 Feb;70(2):584-590.

Pullen GR, Fitzgerald Margaret G, Hosking CS. Antibody avidity determination by ELISA using thiocyanate elution. *J Immun Methods* . 1986 Jan 22;86(1)83-87.

Lee LH, Frasch CE, Falk LA, Klein DL, Deal CD. Correlates of immunity for pneumococcal conjugate vaccines. *Vaccine* . 2003 May 16;21(17-18):2190-6.

Orange JS, Ballow M, Stiehm RE, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol.* 2012 Sep;130(3 Suppl):S1-24.

Pickering JW, Martins TB, Greer RW, et al. A multiplexed fluorescent microsphere immunoassay for antibodies to pneumococcal capsular polysaccharides. *Am J Clin Pathol* . 2002 April;117(4):589-96.

Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weigh-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. *Clin & Diagn Lab Immunol* . 1995 Sept;2:590-7.